Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

Summary

TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented. In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.

Timeline

Start

2008-06

Primary completion

2009-09

Completion

2009-09

Drugs

Indications